Context: Fat-rich diets are involved in many disorders such as obesity and type 2 diabetes (T2D). The Pro12Ala variant of peroxisome proliferator-activated receptor-g (PPARg) is known to modulate body mass index (BMI) and T2D risk. Objective: Our aim was to study the interaction effect between PPARg gene (PPARG) polymorphisms Pro12Ala and 1431C4T and fat intake on incident T2D and BMI in a 9-year prospective cohort drawn from the French general population, the D.E.S.I.R. (Data from an Epidemiological Study on the Insulin Resistance Syndrome) study (n ¼ 4676). Methods: Nutritional intake was assessed by a food frequency self-questionnaire completed by each participant. Statistical analyses included logistic regression, analysis of covariance and haplotype analysis, with adjustment for confounding variables. Results: A high fat consumption (the third sex-specific tertile of fat intake, as a percentage of energy intake) was associated with an increased T2D risk among ProPro and CC homozygotes (P interaction ¼ 0.05, odds ratio (OR) (95% confidence interval (95% CI)) ¼ 1.73 (1.19-2.52) P ¼ 0.004 and OR ¼ 1.85 (1.27-2.71) P ¼ 0.001, respectively) but not in Ala and T carriers. There was a significant interaction effect between Pro12Ala and 1431C4T on BMI (P interaction ¼ 0.004); Ala was associated with lower BMI in CC homozygotes and with higher BMI in T carriers while the opposite was found for ProPro. There was also an interaction effect between Pro12Ala and dietary fat intake on BMI (P interaction ¼ 0.02); AlaAla individuals had a higher BMI than Pro carriers among high fat consumers (27.1 ± 1.0 versus 24.9 ± 0.1 for AlaAla and Pro þ , respectively). There was no interaction effect between the 1431C4T single-nucleotide polymorphism and fat intake on BMI. Conclusion: Our results indicate strong genetic and nutritional interaction effects on BMI and T2D risk at the PPARG locus in a general population.
Introduction
Fat-rich diets contribute to the onset of many disorders such as obesity and type 2 diabetes (T2D). The metabolic response to a high fat diet is, however, influenced by other factors and remains highly dependent on the genetic background of individuals. 1 Peroxisome proliferator-activated receptor-g (PPARg) is a transcription factor that directly regulates target genes, mediating lipid metabolism and adipocyte differentiation. 2 The common Pro12Ala variant of PPARg is expressed only in the adipocyte-specific g2 isoform and results from a C to G transversion in the exon B of the PPARg encoding gene (PPARG). [3] [4] [5] A number of studies have associated the Pro12Ala polymorphism with T2D and hyperglycemia with a protective effect of the minor allele Ala. [6] [7] [8] [9] [10] [11] [12] To a lesser extent, this variant has also been associated with obesity and body weight changes, with conflicting results. [12] [13] [14] [15] [16] [17] [18] Another PPARG polymorphism in linkage disequilibrium with Pro12Ala, the 1431C4T single-nucleotide polymorphism (SNP), has also been associated with T2D. In some studies, it has been shown to modulate the Pro12Ala effect on both T2D and body mass index (BMI). [19] [20] [21] Interaction effects between fat intake and PPARG polymorphisms on BMI and other related parameters have been documented, but the results have not always been concordant. [22] [23] [24] [25] [26] Our aim was to study potential interactions between Pro12Ala and 1431C4T polymorphisms and dietary fat intake on T2D and BMI, in a prospective cohort drawn from a French general population, the D.E.S.I.R. (Data from an Epidemiological Study on the Insulin Resistance Syndrome) study.
Materials and methods

Population
The study population, men and women aged 30-65 years, participated in the cohort D.E.S.I.R., a 9-year follow-up study that aimed to clarify the development of the insulin resistance syndrome. 27 Participants were recruited from 10 health examination centers from the western part of France. These volunteers were insured by the French social security system, which offers periodic health examinations free of charge. All participants signed an informed consent. The protocol was approved by the consultative committee for the protection of participants for biomedical research of Bicêtre Hospital. A total of 4676 men and women were genotyped for Pro12Ala and 1431C4T, and had data available at baseline. Among them, 3646 were non-diabetic at baseline and could be followed for incident diabetes during the 9-year period.
In accordance with the 1997 American Diabetes Association criteria, T2D was defined as fasting plasma glucose X7.0 mmol l À1 and/or treatment by drugs for diabetes. 28 Incident cases (n ¼ 191) were defined for those free of disease at entry, who developed T2D at any time during the follow-up.
Measurements
Weight, height and waist circumferences were measured by trained personnel, and BMI (kg m À2 ) was calculated. Venous blood samples were collected in the morning after a 12-h fast. Fasting plasma glucose was assayed by the glucose oxidase method applied to fluoro-oxalated plasma, using a Technicon RA 1000 (Bayer, Puteaux, France) or a Specific or a Delta Automate (Konelab, Evry, France). A 23-item questionnaire was completed by each participant on the habitual frequency and quantity of consumption of different foods. This questionnaire has been validated by comparison with a dietary history method questionnaire, administrated by trained dieticians with an interview of at least 30 min (correlation coefficients were between 0.44 and 0.80). 29 This validation study enabled the determination of multiple linear regression equations to estimate the main nutrient intakes from the questions on the consumption of different foods. 29 Fat intake was thus determined from the questions on the consumption of meat, fish, pork products, fried foods, butter, cheese and other dairy products. Low, medium and high fat consumption were defined by the sexspecific tertiles of fat intake (as a percentage of total energy). 
Statistical analysis
Departure from Hardy-Weinberg equilibrium was tested using a w 2 with one degree of freedom.
The odds ratios (ORs) for T2D risk associated with genotypes were estimated by multivariable logistic regression adjusted for age, sex, BMI and alcohol consumption. Interactions between genotypes and fat intake on T2D risk were also assessed by multivariable logistic regression analysis, with the same adjustments. The effect of genotypes and the interaction effects of genotypes with fat intake on BMI were tested by analysis of covariance in the individuals non-diabetic at baseline, with adjustments for baseline age, sex, alcohol consumption and physical activity, using Systat for Windows software (version 13) (Systat Software, Inc., Chicago, IL, USA). P-values of multiple pairwise comparisons were corrected by the Bonferroni method. Haplotypic effects on BMI were estimated by the THESIAS software with the same adjustments. 30 
Results
General characteristics of the study population at baseline and at the 9-year follow-up are shown in Table 1 .
The genotypic distributions of both the Pro12Ala and 1431C4T polymorphisms were in Hardy-Weinberg Dietary fat intake and PPARG polymorphisms modulate BMI and T2D risk A Lamri et al equilibrium in the whole cohort at inclusion (P ¼ 0.48 for Pro12Ala and P ¼ 0.98 for 1431C4T polymorphism) with a minor allele frequency of 10.4 and 11.8% for Pro12Ala and 1431C4T SNP, respectively. Both polymorphisms were in linkage disequilibrium (D' ¼ 0.669, r 2 ¼ 0.41, Po0.001).
Influence of PPARG polymorphisms and fat intake on T2D No significant association was found for either of the PPARG SNPs with T2D incidence when tested either separately or in combination. The incidence of T2D was higher in the high fat intake group (third tertile) when compared with the low fat (first tertile, OR (95% confidence interval (95% CI)) ¼ 1.52 (1.02-2.27), P ¼ 0.04) or to the medium fat intake group (second tertile, OR (95% CI) ¼ 1.46 (1.00-2.14), P ¼ 0.05). As there was no difference for T2D incidence between the first and the second tertile groups of fat intake, OR (95% CI) ¼ 0.96 (0.64-1.43), P ¼ 0.83, the interaction effects with the PPARG polymorphisms were investigated using only two categories: low and medium fat intake (first þ second tertile groups) versus high fat intake category (third tertile).
There were significant interaction effects between the PPARG polymorphisms and total energy derived from fat consumption on T2D risk (P interaction ¼ 0.05 for both Pro12Ala and 1431C4T). An increase in fat intake was associated with an increased risk of T2D only among the ProPro and the CC homozygotes ( Table 2) . Table 2 Numbers with and without incident diabetes and odds ratios (95% CI) for cumulative 9-year incidence of type 2 diabetes associated with high fat intake at baseline as compared with medium/low fat intake, according to Pro12Ala, 1431C4T SNPs. The D.E.S.I.R. Study CT and CC genotype, respectively; P ¼ 0.14). Nevertheless, a very significant interaction effect between these SNPs on BMI was detected (P interaction ¼ 0.0006). Ala was associated with lower BMI at baseline in CC homozygotes and with higher BMI in T carriers. Conversely, T was associated with a higher BMI among Ala carriers and with a lower BMI in ProPro homozygotes (Figure 1) . The results were similar when testing the interaction effect on BMI at 9 years or on repeated measures of BMI (data not shown). The genotypes did not influence BMI changes over the follow-up. These results were confirmed by a haplotype study where the genetic background modulated significantly the effect of each SNP at baseline (Figure 2) .
The interaction between fat intake and Pro12Ala on BMI was significant for the recessive model (P interaction ¼ 0.02). In each genotype, a higher fat intake was associated with a higher BMI at baseline; in the high fat consumers group only, the AlaAla homozygotes had a higher BMI than Pro carriers (Figure 3) .
No interaction between 1431C4T SNP and fat intake was detected. There were no significant interactions of PPARG SNPs genotype combinations or haplotypes with fat intake on BMI. All the results remained similar after additional adjustment for drug treatments (data not shown).
Discussion
In previous studies, we have shown a modest association of T2D and impaired fasting glycemia with PPARG polymorphisms, 6 or only a trend. 31 In the present study, we focus on the interaction issue. We report that a high fat intake is associated with the incidence of T2D over a 9-year period, in interaction with PPARG polymorphisms. There was a Dietary fat intake and PPARG polymorphisms modulate BMI and T2D risk A Lamri et al gene-gene interaction effect between these two polymorphisms on BMI and there was also an interaction between fat intake and the Pro12Ala polymorphism.
A high fat intake was associated with an increased T2D risk at 9 years only among the ProPro and the CC homozygotes, but not in the other genotypes. Therefore, the beneficial effect of the Ala allele on T2D risk usually reported 6-12 might be due in part to the lack of response to a higher fat intake for Ala carriers. To our knowledge, this interaction with fat intake on T2D risk has not been described in the literature. Robitaille et al. 26 described a similar effect on waist circumference, and showed that a high fat intake was correlated with an increased visceral adipose tissue accumulation among ProPro individuals only. However, this interaction was not detected in our cohort. The association between Pro12Ala and BMI has been the subject of several studies with controversial results. A metaanalysis with data from 30 independent studies, included cases with different pathologies related to metabolic disorders. In that study, the effect of the Ala allele on BMI was recessive, and AlaAla homozygotes had a higher BMI than ProPro in obese individuals. 18 A second meta-analysis included data from 57 independent studies with healthy participants showed an effect of PPAR on BMI for Caucasians only. In this case, AlaAla individuals had a slightly higher BMI than ProPro. 14 The higher BMI of Ala homozygotes in our study is in agreement with these analyses. Moreover, our results show an interaction between the Pro12Ala SNP and dietary fat intake on BMI. AlaAla homozygotes had significantly higher BMI than Pro carriers among the high fat consumers, but not among the low or medium fat consumers. Similar results have been described in a diabetic population. 24 According to Luan et al., 23 a low polyunsaturated/saturated fatty acid ratio is associated with a higher BMI among Ala carriers. These results are in agreement with ours, since an increase in total fat intake is highly correlated with an increase in saturated fatty acid consumption. A study with Pro12Ala knock-in mice model is also in agreement with our observations: there was a trend for AlaAla mice to have a higher BMI, body weight and fat mass than ProPro homozygotes under a high fat diet. 25 Another study shows results contradictory to ours: Ala carriers had higher BMI among the low fat consumers (first quintile) while an increase in fat intake was associated with an increased BMI in ProPro homozygotes but not in Ala carriers. 22 However, this study included only healthy women. In our results, sex did not modulate the PPARG-fat intake interaction (data not shown). The reason for this difference is unclear. As nutritional habits vary between different populations, this Pro12Ala-fat intake interaction could partially explain the controversial results previously described for the effect of this SNP on BMI in the different ethnic groups. The second polymorphism 1431C4T did not show any direct effect on BMI. Nevertheless, there was an interaction between this SNP and Pro12Ala, affecting BMI. This modulation of 1431C4T on Pro12Ala effect could also explain the conflicting BMI data observed in populations with different Pro12Ala and 1431C4T allelic and haplotype frequencies. A similar interaction effect has previously been described by Doney et al., 19 but with a weaker significance, probably because of low statistical power.
The main results of our study seem paradoxical. A high fat intake increases BMI in AlaAla individuals but increases T2D risk in ProPro homozygotes. This may be in line with the effects of the PPARg agonists, the glitazones which are drugs for treatment of diabetes that increase body weight. However, the results concerning Pro12Ala and fat intake interaction on BMI should be considered with caution as the difference in BMI between genotypes in high fat consumers was no longer significant after Bonferroni correction, probably because of the small number of AlaAla homozygotes in this study. Therefore, this observation needs replication.
The second polymorphism 1431C4T acts similarly to Pro12Ala on T2D risk, but not on BMI, despite the strong linkage disequilibrium between the two SNPs. Nevertheless, the r 2 -value (0.41) indicates that they are not completely correlated. Therefore, the effects of Pro12Ala and fat intake on T2D and BMI could involve two distinct mechanisms. The interaction effect of fat intake with Pro12Ala (and the absence of interaction with 1431C4T) on BMI may be due to the fact that Pro12Ala is specific to PPARg2, the PPARg isoform expressed only in adipose tissue. Indirectly, this may also mean that the effect of Pro12Ala and 1431C4T on T2D could be due to the effect of the protein not only in the adipocytes, but also in other tissues where it is expressed and could imply other variants or mutations of the gene, in linkage disequilibrium with these SNPs.
The Ala allele was associated with a decreased transactivation of the target genes, and a reduced adipogenic capacity due to a reduced DNA-binding capacity. 7, 12 In a study of Pro12Ala knock-in mice, 25 under a chow diet, the pattern of expression of PPARg target genes of PPARG was similar between ProPro and AlaAla mice and only two genes were differentially expressed. Under a high fat diet, a total of 46 genes were differentially expressed between the two genotypes in white adipose tissue, with a majority being downregulated in the AlaAla mice, thus pointing to a different response of these genotype groups to an increase in fat intake that could have an impact on BMI and diabetes risk, in agreement with what we observed in our study. The prospective design of the D.E.S.I.R. study allowed us to avoid many biases of case-control studies. Nevertheless, at each follow-up examination, glycemia was measured only once, whereas T2D is diagnosed with at least two measures of glycemia. Our study has another important limitation: although it has been validated, the data from the selfquestionnaire remain semi-quantitative and do not allow the estimation of these interactions with different fat components (monounsaturated, polyunsaturated or saturated fatty Dietary fat intake and PPARG polymorphisms modulate BMI and T2D risk A Lamri et al acids). Unfortunately, plasma fatty acids could not be measured either.
In conclusion, our results are indicative of strong genetic and nutritional interaction effects on BMI and T2D at the PPARG locus.
